- Ophthalmic Suspension 0.1%
Decreases inflammation by blocking prostaglandin H synthase, an enzyme required for prostaglandin production.
Indications and Usage
Treatment of pain and inflammation associated with cataract surgery.
Dosage and AdministrationAdults and Children 10 yr of age and older
Ophthalmic 1 drop to affected eye 3 times daily beginning 1 day prior to cataract surgery and continued on the day of surgery and through the first 2 wk of the postoperative period.
- Shake well before use.
- May be used in conjunction with other topical ophthalmic medications (eg, beta-blockers).
Store at 36° to 77°F.
None well documented.
Laboratory Test Interactions
None well documented.
Hypertension (1% to 4%).
Headache (1% to 4%).
Capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, sticky sensation (5% to 10%); conjunctival edema, corneal edema, dry eye, lid-margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, vitreous detachment (1% to 5%).
Nausea/vomiting (1% to 4%).
Sinusitis (1% to 4%).
Category C .
Safety and efficacy not established in children younger than 10 yr of age.
Special Risk Patients
Use with caution in patients with complicated ocular surgery, corneal denervation, corneal surface disease (eg, dry eye syndrome), rheumatoid arthritis, known bleeding tendencies, or repeat ocular surgeries within a short period of time.
There is a potential for increased bleeding time caused by interference with thrombocyte aggregation.
Use of product more than 1 day prior to surgery or beyond 14 days post surgery may increase the risk for occurrence and severity of corneal adverse reactions.
Because of potential cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, use caution when treating patients previously exhibiting sensitivity to these agents.
Healing may be slowed or delayed.
Continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, which may be sight threatening.
- Advise patients not to administer while wearing contact lenses.
Copyright © 2009 Wolters Kluwer Health.